$GRAL: The FDA Votes on Grail's Cancer Blood Test Tomorrow. The Stock Already Paid Itself a Third for the Paperwork.
Grail jumped 33.7% after FDA staff flagged no major concerns with its Galleri multi-cancer blood test. The advisory panel votes Wednesday, September 23. The share count, the $861M balance-sheet clock, and the scenario zones for a $4.8B binary.
